Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| Tesamorelin | GHRH analog peptide | Moderate | FDA-approved only for HIV lipodystrophy, off-label elsewhere |
| CJC-1295 / Ipamorelin Stack | GHRH analog + GHRP secretagogue | Limited | Not FDA-approved, sold research use only |
| BPC-157 | Pentadecapeptide | Limited | Not FDA-approved, sold as research-use-only, gray-market |
| TB-500 | Thymosin Beta-4 fragment peptide | Emerging | Not FDA-approved, sold for research purposes only |
| BPC-157 + TB-500 Wolverine Stack | Pentadecapeptide + thymosin fragment stack | Emerging | Not FDA-approved, sold "for research purposes only" |
The ranking
Tesamorelin
Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analog that works by prompting the pituitary gland to release the body’s own growth hormone, which in turn raises IGF-1 and can support the mTOR pathway involved in muscle protein synthesis.
It is the only compound in this GH-secretagogue category with a genuine FDA approval, based on human trial data, though that approval is specifically for HIV-associated lipodystrophy rather than muscle growth or athletic performance.
It ranks first here because it has the strongest documented human evidence tier among injectable GH-axis peptides discussed for muscle growth, even though its labeled use is different.
Related GHRH-class research in older men (human RCT) showed improvements in some strength measures like upright row and shoulder press, though not consistent gains in physical function or IGF-1 levels, giving a sense of what this mechanism can and cannot do.
Strengths
- FDA-approved status means it has passed human clinical trials, unlike most peptides in this category
- Mechanism (GHRH to pituitary to GH to IGF-1) is well-established and consistent across sources
- Related GHRH-analog human research shows measurable strength changes in some outcomes
Limitations
- Approved indication is HIV-associated lipodystrophy, not muscle growth, so any muscle benefit is off-label and unproven for that purpose
- Human GHRH research shows inconsistent effects on physical function and IGF-1 levels
- Related GH-secretagogue trials (capromorelin) report side effects like fatigue, insomnia, and increased fasting glucose
- Best for
- Those wanting the most human-studied GH-axis peptide, not muscle-specific use
- Evidence
- Moderate
- Status
- FDA-approved only for HIV lipodystrophy, off-label elsewhere
CJC-1295 / Ipamorelin Stack
CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog and Ipamorelin is a growth-hormone-releasing peptide (GHRP); together they are marketed as a “stack” meant to stimulate the pituitary to release the body’s own GH in a pulsatile pattern, raising IGF-1 and theoretically supporting muscle protein synthesis via the mTOR pathway.
This mechanism mirrors what has been studied in related GH secretagogues like tesamorelin and capromorelin, but no dedicated human trials on muscle growth outcomes for this specific CJC-1295/Ipamorelin combination were found; the supporting evidence is indirect, drawn from animal data and adjacent human secretagogue studies rather than direct trials of the stack itself.
Retail and clinic-adjacent sources present it as an established “standard stack,” while higher-weighted editorial and clinical sources treat GH-releasing peptides overall as having only modest, compound-specific human evidence and caution against unregulated injectable use.
Strengths
- Shares a plausible, well-described GH to IGF-1 to mTOR mechanism with peptides that do have some human data (tesamorelin, capromorelin)
- Framed as more "physiologic"/pulsatile than injecting synthetic HGH directly
Limitations
- No dedicated human trials measuring muscle growth from this specific stack; evidence is indirect and largely animal-based
- Not FDA-approved, unregulated, and sold "for research purposes only" with contamination and quality-control concerns
- GH secretagogues as a class are prohibited under WADA anti-doping rules
- Best for
- Those exploring GH-axis stimulation under close clinical supervision
- Evidence
- Limited
- Status
- Not FDA-approved, sold research use only
BPC-157
BPC-157 is a synthetic pentadecapeptide often called a “recovery” peptide, marketed for muscle and tendon healing. Animal studies show accelerated muscle healing, including reversal of corticosteroid-impaired healing, giving it the most consistent preclinical support among gray-market recovery peptides.
Human evidence, however, is limited to a single small case series in knee pain patients, which had significant methodological flaws and no control group.
A 2026 American Journal of Sports Medicine review concluded more safety and efficacy research is needed before any recommendations can be made, which is why it ranks below peptides with human trial data.
Strengths
- Multiple animal studies show accelerated muscle and tendon healing
- Preclinical data includes reversal of corticosteroid-impaired healing
Limitations
- Only one small, uncontrolled human case series exists, with major methodological flaws
- Not FDA-approved; sourced from unregulated "research purposes only" suppliers with contamination risk
- 2026 AJSM review states insufficient safety/efficacy data exist for clinical recommendations
- Best for
- Those tracking preclinical tendon/muscle healing research, not clinical use
- Evidence
- Limited
- Status
- Not FDA-approved, sold as research-use-only, gray-market
TB-500
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in cell migration and tissue repair processes. It is frequently marketed alongside BPC-157 in the “recovery peptide” category, often referenced in the same gray-market discussions and product listings.
Per the research consensus, peptides in this category are supported mainly by animal and preclinical work, with essentially no controlled human clinical data available for TB-500 specifically.
Where human data exists for related recovery peptides like BPC-157, it is limited to small, uncontrolled case reports, and no comparable human evidence is documented for TB-500 in the sourced research. This places TB-500 at an earlier, more speculative stage of evidence than either oral collagen peptides or growth-hormone-releasing peptides discussed elsewhere in this guide.
Strengths
- Falls within the general "recovery peptide" mechanism class discussed alongside BPC-157 in tissue-repair contexts
- Attracts ongoing research and consumer interest, keeping it part of the broader regulatory review conversation around compounded peptides
Limitations
- No human clinical trial data identified in the research; support is animal/preclinical or anecdotal only
- Not FDA-approved for human use and sold strictly as a "research purposes only" product
- Safety, dosing, and long-term effects remain unestablished, consistent with expert caution around unregulated injectable peptides
- Best for
- Preclinical interest in soft tissue and tendon repair claims
- Evidence
- Emerging
- Status
- Not FDA-approved, sold for research purposes only
BPC-157 + TB-500 Wolverine Stack
This pairing combines BPC-157, a synthetic pentadecapeptide studied mainly in animal models for tissue repair, with TB-500, a synthetic fragment of Thymosin Beta-4. The nickname reflects online claims about rapid healing, but the research document contains no human trial data on the two compounds used together.
BPC-157 alone has shown accelerated muscle healing in animal studies, including reversal of corticosteroid-impaired healing, but human evidence is limited to a single case series on knee pain with no control group and significant methodological flaws.
A 2026 review in the American Journal of Sports Medicine concluded more safety and efficacy research is needed before any recommendations can be made. TB-500 is named across sources but lacks comparable detail in the underlying research, and no combination-specific human studies were identified.
Strengths
- Animal studies suggest BPC-157 may accelerate muscle and tendon healing
- BPC-157 reversed corticosteroid-impaired healing in animal models
Limitations
- No human trials exist for the BPC-157 + TB-500 combination itself
- The only human data on BPC-157 alone is a single uncontrolled case series
- Sold unregulated and "for research purposes only," with contamination and quality-control risk
- Best for
- Preclinical research interest in tissue repair, not clinical use
- Evidence
- Emerging
- Status
- Not FDA-approved, sold "for research purposes only"
How we picked
Each peptide was ranked by tier of human evidence first (RCT data, case series, or none), then by mechanism plausibility (GH to IGF-1 to mTOR) and regulatory/safety standing.
Capromorelin and GHRH-analog secretagogues rank higher because they have real human RCT data for GH/IGF-1 and lean-mass effects (e.g., the 395-person capromorelin trial), even though Tesamorelin’s only FDA approval is for HIV lipodystrophy, not muscle growth; the rest rely on indirect, animal, or single uncontrolled human data., even though its FDA approval is for HIV lipodystrophy, not muscle growth; the rest rely on indirect, animal, or single uncontrolled human data.
This ranking reflects evidence strength only, not a recommendation to use any of these compounds, and none are FDA-approved for muscle growth specifically.
Important safety note
Every compound on this list except tesamorelin is sold in an unregulated, "for research purposes only" market, and even tesamorelin's human safety data comes from a different approved use. Contamination, unknown long-term effects, and lack of controlled human muscle-growth trials are consistent concerns across sources. Anyone considering these should talk to a qualified clinician first; this guide does not provide dosing or usage instructions.
Frequently asked questions
Which peptide has the strongest human evidence for muscle-related effects?
Tesamorelin, an FDA-approved GHRH analog, has real human RCT data showing GH and IGF-1 increases. It's not approved for muscle growth, but it has more rigorous human data than any other peptide on this list.
Is the CJC-1295/Ipamorelin stack backed by human muscle-growth studies?
No. It shares a mechanism with peptides that do have human data (like tesamorelin and capromorelin), but there are no dedicated human trials on this specific stack, only indirect and animal evidence.
Does BPC-157 actually help repair muscle in humans?
Animal studies consistently show healing benefits, but human evidence is limited to one small, uncontrolled case series for knee pain. A 2026 review says more safety and efficacy research is needed before conclusions can be drawn.
Is TB-500 better studied than BPC-157?
No, it's less studied. TB-500 is cited alongside BPC-157 for tissue repair claims but has even less human data, essentially preclinical and animal research only.
Is the BPC-157 + TB-500 "Wolverine Stack" supported by research?
No. It combines two compounds that each lack human trial data, and there are no studies on the combination itself. This is the weakest evidence tier of the group.
Are any of these peptides FDA-approved for muscle growth?
No. Tesamorelin is FDA-approved, but only for HIV-associated lipodystrophy. None of the peptides here are approved specifically for muscle growth.
Are these peptides legal to buy and use?
Most are sold labeled "for research purposes only" and are not regulated or approved for human use, which raises open legal and quality-control questions. This status can change, so treat any current claims as time-sensitive.